Clinical Trial Finder

Inclusion Criteria:

• - Patient must be ≥18 years of age.

• - Diagnosis of one of the following: - MUM: Uveal melanoma with histological or cytological confirmed metastatic disease.

• - Non-MUM: Advanced cutaneous melanoma, colorectal cancer, or other solid tumor that has progressed following prior standard therapies or that has no satisfactory alternative therapies and has evidence of GNAQ/11 hotspot mutation.

• - Measurable disease.

• - Eastern Cooperative Oncology Group ≤1 and expected life expectancy of > 3 months.

• - Adequate organ function at screening.

• - Adequate contraceptive measures for non-sterilized male and female patients of childbearing potential.

Inclusion Criteria:

Inclusion Criteria:

• - Prior chemotherapy other therapies as applicable or major surgeries must have been completed at least 4 weeks prior to initiation of crizotinib.

• - Patients with preexisting peripheral neuropathy can be included if it is Grade 1 or lower, prior to initiation of crizotinib.

Exclusion Criteria:

• - Known symptomatic brain metastases.

• - Previous treatment with a PKC inhibitor.

• - Known MSI-H/dMMR tumors who have not previously received immune checkpoint inhibitors.

• - Adverse events from prior anti-cancer therapy that have not resolved.

• - Known acquired immunodeficiency syndrome (AIDS)-related illness, hepatitis B virus, or hepatitis C virus.

• - Active infection requiring ongoing therapy.

• - Recent surgery or radiotherapy.

• - Prior gastrectomy or upper bowel removal or any other gastrointestinal disorder or defect.

• - Females who are pregnant or breastfeeding.

• - Impaired cardiac function.

• - Treatment with prohibited medications that cannot be discontinued prior to study entry.

• - For patients receiving IDE196 powder-in-capsule (PIC) formulation or crizotinib, allergy to mammalian meat products and gelatin.

• - Prior treatment with a MEK inhibitor.

• - History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.

• - History of interstitial lung disease.

• - History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to first dose.

• - Concurrent neuromuscular disorders that are associated with elevated creatine phosphokinase (CPK) - Uncontrolled arterial hypertension despite medical treatment.

• - Allergy to binimetinib or its components.

• - History of syncope.

Exclusion Criteria:

• - Prior therapy directly targeting ALK, MET, or ROS1.

• - Spinal cord compression.

• - History of pneumonitis or interstitial lung disease.

Arms

Interventions